Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity

Biochemical Pharmacology

Volumn 86, Issue 2, 2013, Pages 286-296

  Kahnt, Astrid Stefanie ^a   Rorsch, Florian ^a   Diehl, Olaf ^a   Hofmann, Bettina ^a   Lehmann, Christoph ^a,b   Steinbrink, Svenja Dorothea ^a   Angioni, Carlo ^a   Geisslinger, Gerd ^a   Grosch, Sabine ^a   Steinhilber, Dieter ^a   Maier, Thorsten Jurgen ^a  

^a GOETHE UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Leukotriene; Montelukast; MPGES 1; PGE2; Pranlukast; Prostaglandin; Zafirlukast

Indexed keywords

LIPOPOLYSACCHARIDE; MICROSOMAL PROSTAGLANDIN E2 SYNTHASE 1; MONTELUKAST; PRANLUKAST; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ARTICLE; CARCINOMA CELL; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; LEUKOCYTE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

EID: 84884902318     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.05.005     Document Type: Article

References (43)

1. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinylleukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007;27:469-527. (Pubitemid 46984658)
2. Watson N, Magnussen H, Rabe KF. Inherent tone of human bronchus: role of eicosanoids and the epithelium. Br J Pharmacol 1997;121:1099-104. (Pubitemid 27303577)
3. Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2013;85:336-49.
4. Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy 2013;40:1732-41.
5. Yamauchi K, Tanifuji Y, Pan LH, Yoshida T, Sakurai S, Goto S, et al. Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics. J Asthma 2001;38:51-7. (Pubitemid 32246194)
6. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998;157:1381-9.
7. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-8. (Pubitemid 29411228)
8. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998;53:835-41. (Pubitemid 28459539)
9. Tintinger GR, Feldman C, Theron AJ, Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? Scientific World Journal 2013;10:2403-13.
10. Ramires R, Caiaffa MF, Tursi A, Haeggstrom JZ, Macchia L. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun 2004;324:815-21. (Pubitemid 39345588)
11. Tahan F, Jazrawi E, Moodley T, Rovati GE, Adcock IM. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity. Clin Exp Allergy 2008;38:805-11. (Pubitemid 351550673)
12. Anderson R, Theron AJ, Gravett CM, Steel HC, Tintinger GR, Feldman C. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMPdependent mechanism. Br J Pharmacol 2009;156:105-15.
13. Robinson AJ, Kashanin D, O'Dowd F, Williams V, Walsh GM. Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT(1)R antagonism. J Leukoc Biol 2008;83:1522-9. (Pubitemid 351960334)
14. Schmidt R, Coste O, Geisslinger G. LC-MS/MS-analysis of prostaglandin E2 and D2 in microdialysis samples of rats. J Chromatogr B Analyt Technol Biomed Life Sci 2005;826:188-97. (Pubitemid 41446449)
15. Thoren S, Jakobsson PJ. Coordinate up-and down-regulation of glutathionedependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells inhibition by NS-398 and leukotriene C4. Eur J Biochem 2000;267:6428-34.
16. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-72. (Pubitemid 32927924)
17. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007;59:207-24. (Pubitemid 47481434)
18. Koeberle A, Pollastro F, Northoff H, Werz O. Myrtucommulone: a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br J Pharmacol 2009;156:952-61.
19. Koeberle A, Northoff H, Werz O. Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol. Biochem Pharmacol 2009;77:1513-21.
20. Cote B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, et al. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 2007;17:6816-20. (Pubitemid 350061309)
21. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001;119:1533-46. (Pubitemid 32686041)
22. Garcia-Marcos L, Schuster A, Perez-Yarza EG. Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf 2003;26:483-518. (Pubitemid 36629786)
23. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. Cochrane Database Syst Rev 2000. CD002314.
24. Traut JL, Macdonald ES, Spangler ML, Saxena S. Montelukast for symptom control of interstitial cystitis. Ann Pharmacother 2013;45:e49.
25. Fujiwara H, Konno R, Netsu S, Odagiri K, Taneichi A, Takamizawa S, et al. Efficacy of montelukast, a leukotriene receptor antagonist, for the treatment of dysmenorrhea: a prospective, double-blind, randomized, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2013;148:195-8.
26. Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF, et al. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 2001;41: 612-9. (Pubitemid 32493355)
27. Knorr B, Maganti L, Ramakrishnan R, Tozzi CA, Migoya E, Kearns G. Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. J Clin Pharmacol 2006;46:620-7.
28. Brocks DR, Upward JW, Georgiou P, Stelman G, Doyle E, Allen E, et al. The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers. Eur J Clin Pharmacol 1996;51:303-8. (Pubitemid 26422978)
29. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006;27:495-503. (Pubitemid 43372522)
30. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged or = 6 years. Clin Exp Allergy 2001;31:77-87. (Pubitemid 32158764)
31. Noonan GP, Williams B, Angner R, Lu S, Knorr B, Reiss TF. Use of oral montelukast in the treatment of asthma. Compr Ther 2001;27:148-55. (Pubitemid 32549891)
32. Ricciotti E, FitzGerald GA. rostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2013;31:986-1000.
33. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50. (Pubitemid 34178297)
34. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11:81s-110s.
35. Watanabe K. Prostaglandin synthase. Prostaglandins Other Lipid Mediat 2002;68-69:401-7.
36. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103:147-66. (Pubitemid 39209041)
37. Luster AD, Tager AM. T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 2004;4:711-24. (Pubitemid 39223077)
38. Liang X, Wu L, Hand T, Andreasson K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neurochem 2005;92:477-86. (Pubitemid 40189451)
39. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999;5:698-701. (Pubitemid 29289435)
40. Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006;12:148-58.
41. Singh D, Cadden P, Hunter M, Pearce Collins L, Perkins M, Pettipher R, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J 2013;41:46-52.
42. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Collins LP, Hunter MG, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, doubleblind trial. Allergy 2012;67:1572-9.
43. Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol 2013;131:339-45.